IGF-1 LR3
Also known as: Long R3 IGF-1, LR3-IGF-1, Insulin-like Growth Factor 1 Long R3
Primary recreational use: Muscle growth and performance enhancement
What is IGF-1 LR3?
IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1 with enhanced potency due to structural modifications. It is primarily used in research settings for its potential benefits in muscle growth and tissue repair. Despite its scientific intrigue, IGF-1 LR3 has not been approved for human use by any regulatory agency and is associated with significant risks, including hypoglycemia and potential cancer progression.
Primary Benefits
Promotes muscle growth. Enhances tissue repair. Improves glucose uptake.
How It Works
IGF-1 LR3 binds to the IGF-1 receptor, activating the PI3K/Akt/mTOR and MAPK/ERK pathways, which stimulate cellular growth and protein synthesis. The structural modifications reduce binding to IGF-binding proteins, increasing free circulating levels and extending its half-life to 20-30 hours.
Safety Tips
Precautions reported in community discussions and literature. This is not a complete list.
- 1.DON'T start with high doses; begin with the lowest effective dose to assess tolerance.
- 2.NEVER use IGF-1 LR3 if you have a history of cancer or undiagnosed growths.
- 3.AVOID using without consuming carbohydrates immediately after injection to prevent hypoglycemia.
- 4.DON'T use for periods longer than 4-6 weeks due to receptor desensitization risks.
- 5.NEVER reconstitute with BAC water, use 0.6% acetic acid instead to maintain stability.
- 6.AVOID injecting before sleep to reduce the risk of overnight hypoglycemia.
- 7.DON'T share needles or vials to prevent contamination and infection.
- 8.NEVER use in competitive sports, as it's prohibited and will cause a failed drug test.
- 9.AVOID using without medical supervision, especially if you have metabolic or oncologic risks.
- 10.DON'T skip breaks between cycles; allow at least an equal period off for receptor recovery.
Use Contexts
Different purposes have different protocols, dosing, and considerations
Muscle growth and performance enhancement
moderate evidenceUsed by athletes and bodybuilders to promote muscle growth, enhance protein synthesis, and improve recovery.
Evidence: Supported by animal studies showing significant muscle mass gains, but lacks controlled human trials.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Post-workout
Notes: Ensure adequate carbohydrate intake post-injection to prevent hypoglycemia.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| Intermediate Research Use | 40-60mcg | Once daily | Subcutaneous or intramuscular |
| Advanced Research Protocol | 80-100mcg | Once daily or split AM/PM | Subcutaneous or site-specific IM |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Organ hypertrophy
- Cancer proliferation concern
Injection-Specific Warnings
- Proper injection technique is critical to avoid site reactions
- Monitor blood glucose regularly
Storage
Exploration of metabolic and regenerative capabilities
limited evidenceUsed in experimental settings for studying tissue regeneration, glucose metabolism, and potential therapeutic applications.
Evidence: Primarily supported by preclinical animal studies and in vitro data showing enhanced cellular proliferation and tissue repair.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Varies by study focus
Notes: Experimental settings require controlled environments to minimize risks.
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| Women's Research Protocol | 10-20mcg | Once daily | Subcutaneous only |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Potential enhanced tumor growth
Injection-Specific Warnings
- Requires careful monitoring for adverse reactions
Storage
Harm Reduction Information
Quality Concerns
- Purity and contamination risks from unregulated sources
- Degradation if improperly reconstituted
Safety Tips
- Use sterile technique and rotate injection sites to minimize irritation
- Start with lower doses to gauge tolerance
- Ensure carbohydrate intake post-injection to prevent hypoglycemia
- Consult a healthcare provider before use, especially if you have metabolic concerns
Warning Signs to Stop
- New growths or changes in existing moles
- Severe hypoglycemia symptoms
- Injection site infections or persistent pain
Seek Medical Help Immediately If
- Severe hypoglycemia or loss of consciousness
- Signs of allergic reaction
- Severe muscle or joint pain post-injection
Frequently Asked Questions
Common questions about IGF-1 LR3
How long until I see effects?
IGF-1 LR3 effects typically begin to appear within 1-2 weeks of starting use, with more notable changes after 2-4 weeks.
What time of day should I take it?
It's recommended to administer IGF-1 LR3 once daily, ideally post-workout, to align with the period of heightened receptor sensitivity.
How can I minimize side effects?
To minimize side effects, particularly hypoglycemia, consume 30-60g of fast carbohydrates immediately after injecting IGF-1 LR3.
Does tolerance develop?
Yes, receptor desensitization can occur after about 6 weeks, so cycling with equal breaks is recommended for IGF-1 LR3.
How should I store it?
Store lyophilized IGF-1 LR3 at -20°C long-term. Once reconstituted with acetic acid, it should be kept at 2-8°C and protected from light.
Do I need to cycle it?
Yes, IGF-1 LR3 should be cycled with maximum 4-6 week periods followed by equal-length breaks to allow receptor recovery.
Reported Combinations
Compounds reported to be used alongside IGF-1 LR3 in community discussions
BPC-157
Supports enhanced muscle recovery and tissue repair.
CJC-1295/Ipamorelin
Combining with growth hormone secretagogues may enhance muscle growth effects.
Vitamin D
May support musculoskeletal health alongside IGF-1 LR3.
Reported Interactions
Interactions reported in literature and community discussions.
Avoid combination due to increased risk of severe hypoglycemia.
Co-administration increases risk for dangerous hypoglycemia.
Monitor as combination may exacerbate side effects.
Dose-dependent interaction; monitor glucose regulation.
Generally safe but may affect blood sugar dynamics.
Reconstitution Calculator
100 units = 1 mL
Safety Tips
- Always consult a licensed medical professional for dosing and reconstitution instructions.
- Always double check your units. Mixing up mg and mcg can be very dangerous.
- Make sure to select your syringe type. U-100 and U-50 syringes have different units.
- Ensure you're not adding more BAC than your vial can hold. Most vials have maximum capacities listed.
This calculator is for informational and educational purposes only. It does not provide medical advice, dosing recommendations, or safety determinations. Reference ranges shown are compiled from publicly available sources and are not a substitute for guidance from a licensed healthcare professional.
Legal Status by Region
Regulatory status varies by country
USA
Not approved; sold as research chemical
UK
Unlicensed; import restrictions
EU
Not authorized
Australia
Prescription only; not available
Canada
Not authorized
Explore More Research
Browse our database of peptide research information compiled from published literature and community sources.
Citations
Last updated: October 6, 2023